NASDAQ: TXG

10x Genomics (TXG) Stock Analysis & Forecast

Nov 13 close

$58.19−0.91 (−1.5%)

Gekko Brief

AI summaryNov 9 close

10x Genomics reported third-quarter 2026 results this week, with revenue beating estimates and a per-share loss of $0.15 versus a year-ago loss of $0.22. The company raised its full-year 2026 sales guidance to $625 million-$635 million, up from $610 million-$630 million and above the consensus estimate of $619.854 million, citing strong demand for its Atera spatial biology platform, which nearly all of the top 20 biopharma companies have now purchased or used via Catalyst Research Services, which booked over 100 customers in its first five months. The company also launched Sentira Single Cell, a Claude-powered AI tool aimed at simplifying data analysis. Despite the raised guidance, shares reacted with a last-earnings move of -12.2%.

TXG closed at $65.05, up 9.7% on the day, with the stock sitting between its 50-day average of $74.02 and 200-day average of $41.80. The one-month return stands at -19.3%, while six-month and one-year returns remain sharply positive at 217.3% and 400.4%. The GekkoIndex reads 62.3, placing the stock in the Accumulation zone, down 2.2 over the past five readings. Price sits 13.7% below Gekko Fair Value of $75.37.

The next earnings date falls on 11 February 2027, 93 days out, beyond a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal appeared, with call premium of $2,178,765 and no put premium recorded. One billionaire holder and one trailblazer holder are noted. Analyst coverage spans 15 firms, with 5 at buy and 10 at hold, and a consensus target of $77.50, implying 19.1% upside. Seasonally, the next 20 trading days have averaged a 4.5% gain over 5 years, rising in 3 of those years.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

10x Genomics price vs fair value

$71.61$58.19Nov ’25May ’26Nov ’26
Close $58.19200-day averageGekko Fair Value $71.61

10x Genomics quick facts

Market cap
$7.00B
P/E ratio
—
Forward P/E
5000
EPS, TTM
−$0.52
Revenue, TTM
$618.6M
Profit margin
-10.8%
Dividend yield
—
Beta
2.03
Volume
2.12M avg 3.17M
1-year return
+248.7%
Typical daily move
±12.6%
Typical 20-day move
±13.4%
50-day average
$73.92
200-day average
$42.58
Next earnings
Feb 11 after close
Shares outstanding
121.5M
52-week range
$15.12$102.81

10x Genomics swing-trade checklist

10x Genomics scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $58.19 sits between the 50-day ($73.92) and 200-day ($42.58) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    64, Accumulation

    Reading 64 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    18.7% below

    Price is 18.7% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +0.9% on average

    From this point in the calendar, the next 20 trading days averaged +0.9% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

10x Genomics stock chart and price history

10x Genomics closed at $58.19 on Nov 13, 2026, +248.7% over the past year, inside a 52-week range of $15.12 to $102.81.

Close50-day average200-day averageVolume
10x Genomics share price, past year, with 50-day and 200-day moving averages and volume$20$40$80$100DecJan 2026FebMarAprMayJunJulAugSepOctNov58.19

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−19.6%
3 months
+0.3%
6 months
+174.5%
1 year
+248.7%
The full TXG chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TXG in Gekko

Follow 10x Genomics through every session

Put TXG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track TXG in GekkoFree for 7 days. No credit card required.

About 10x Genomics

10x Genomics builds tools that let scientists study biology at the level of individual cells and within tissue samples. Its equipment, supplies and software are used to examine gene activity, immune cell behavior, and the physical structure of DNA, giving researchers a detailed picture of how biological systems function. The company is particularly known for its Chromium and Chromium Connect instruments, which work alongside microfluidic chips, slides and reagents to support this kind of single-cell analysis.

Much of its product range centers on single-cell applications built around the Chromium platforms, covering gene expression, immune profiling, chromatin accessibility, and combined measurement of genetic and epigenetic activity across large numbers of cells at once. The company also produces a spatial gene expression solution called Visium, which maps where gene activity occurs within tissue sections and can be paired with immunofluorescence to detect proteins alongside gene expression. Customers span academic institutions, government bodies, and biopharmaceutical and biotechnology organizations, and the company's reach extends across North America, Europe, the Middle East, Africa, China and the Asia Pacific.

10x Genomics is headquartered in Pleasanton, California, and traces its founding to 2012, having operated for a time under the name 10X Technologies before adopting its current name. Its shares are listed on the NASDAQ under the ticker TXG.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
10xgenomics.com

10x Genomics GekkoIndex: the smart money zone

10x Genomics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64, in the Accumulation zone, down 1.4 points over five sessions.

010064Accumulation

Down 1.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying88−0.3%−1.7%−6.1%−12.6%
Accumulation (current zone)208−0.2%−0.2%+2.1%+8.6%
Neutral358+1.9%+3.7%+7.0%+17.9%
Distribution47−2.2%−0.4%−0.4%+28.8%
Selling1Too few readings yet

Average TXG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the TXG price, zone by zone.Track TXG in Gekko

Is 10x Genomics stock overvalued? Gekko Fair Value

10x Genomics trades 18.7% below Gekko Fair Value of $71.61, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what 10x Genomics shares are worth, recalculated every trading day.

$71.61

Gekko Fair Value, Nov 14, 2026

18.7% Undervalued

At the end of Aug 2026 the price was 26.9% above the estimate.

Gekko Fair ValueShare price, month end
$72$58Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open TXG in Gekko

10x Genomics insider and Congress trading

No open-market insider purchases were filed for 10x Genomics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for TXG in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every TXG insider filing, plotted on the chart in Gekko.Open TXG in Gekko

Congress trades last 90 days

No trades in TXG were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for TXG, plotted on the chart in Gekko.Open TXG in Gekko

Buybacks

10x Genomics has been buying back its own shares.

Bought back, year ended Dec 31, 2017
$80K
As a share of market cap
0.00%

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Oct 29, $2.18M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

2of the funds Gekko tracks hold TXG.

0added2opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

10x Genomics earnings: next date and track record

10x Genomics reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±6.8%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+1.0%Feb ’25+5.5%May ’25−2.9%Aug ’25+13.0%Nov ’25−5.4%Feb ’26−5.0%May ’26+9.6%Aug ’26−12.2%Nov ’26

Last earnings call, Nov 5, 2026 AI summary

What they said
10x Genomics reported Q3 2026 revenue of $151 million, up 1% year-over-year, with key highlight being commercial shipments of Atera spatial biology platform. Nearly all top 20 biopharma companies have purchased Atera systems or Catalyst services. Catalyst Research Services booked over 100 customers in its first 5 months. Consumables showed continued strength. Management positions Atera as critical infrastructure for AI-driven biology.
Guidance
Management did not provide specific revenue or earnings targets in this excerpt. CFO Adam Taich's detailed outlook was referenced but not included. Key focus is ramping Atera production and expanding platform capabilities including onboard automation.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 5, 2026−$0.15
est −$0.27
+43.8%$150.7M
est $148.0M
+1.8%−12.2%
Aug 6, 2026−$0.14
est −$0.23
+39.1%$151.0M
est $146.7M
+3.0%+9.6%
May 7, 2026−$0.10
est −$0.29
+65.5%$150.8M
est $146.4M
+3.0%−5.0%
Feb 12, 2026−$0.13
est −$0.19
+31.6%$166.0M
est $159.7M
+4.0%−5.4%
Nov 6, 2025−$0.22
est −$0.07
−214.3%$149.0M
est $142.5M
+4.6%+13.0%
Aug 7, 2025$0.28
est −$0.35
+180.0%$172.9M
est $139.5M
+23.9%−2.9%
May 8, 2025−$0.36
est −$0.45
+20.0%$154.9M
est $145.3M
+6.6%+5.5%
Feb 12, 2025−$0.40
est −$0.29
−37.9%$165.0M
est $165.0M
0.0%+1.0%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

10x Genomics stock forecast and analyst price targets

Analysts’ average 12-month price target for 10x Genomics is $68.14, +17.1% from the last close, from 15 firms rating the stock in the last 90 days.

$68.14consensus 12-month target, +17.1% from the last close
Low $55High $110
Buy5
Hold10
Sell0

Each firm’s latest rating in the last 90 days: 15 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11StephensHold, maintained$65+11.7%
Nov 9BarclaysBuy, maintained$70+20.3%
Nov 9UBSHold, reiterated$61+4.8%
Nov 9J.P. MorganHold, reiterated$65+11.7%
Nov 6TD CowenHold, maintained$55−5.5%
+2.1%average 20-day move after past Accumulation readings
+0.9%average move over the next 20 trading days in the last 5 years
±12.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

10x Genomics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, 10x Genomics averaged +0.9% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−13.7%2021−9.6%2022+28.4%2023+0.6%2024−0.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.7%2 of 5
Next 10 trading days+2.6%3 of 5
Next 15 trading days+2.2%3 of 5
Next 20 trading days+0.9%2 of 5
Next 30 trading days+3.5%2 of 5

For scale, TXG’s typical 20-trading-day move in either direction is about 13.4%.

10x Genomics market cap and key statistics

10x Genomics’s market cap is $7.00B and revenue of $618.6M over the last twelve months.

Valuation

Market cap
$7.00B
Forward P/E
5000
EPS, TTM
−$0.52
Gekko Fair Value
$71.61

Trading

Volume
2.12M
Avg volume, 20 days
3.17M
52-week high
$102.81
52-week low
$15.12
Shares outstanding
121.5M

Financials

Revenue, TTM
$618.6M
Profit margin
-10.8%
Return on equity
-8.3%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.03
Typical daily move
±12.6%
Typical 20-day move
±13.4%

10x Genomics peers

10x Genomics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

10x Genomics stock FAQ

What is 10x Genomics’s market cap?

10x Genomics’s market cap is $7.00B at the Nov 13, 2026 close of $58.19, with 121.5M shares outstanding.

What is the 10x Genomics stock forecast?

The consensus analyst 12-month price target for 10x Genomics is $68.14, +17.1% from the last close. Of the 15 firms that rated the stock in the last 90 days, 5 rate it a buy, 10 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is 10x Genomics stock overvalued or undervalued?

On Gekko’s estimate 10x Genomics is undervalued: the Nov 13, 2026 close of $58.19 is 18.7% below Gekko Fair Value of $71.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does 10x Genomics report earnings next?

10x Genomics is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of −$0.18 per share on revenue of $177.7M. 10x Genomics beat the earnings estimate in 6 of its last 8 reports, moving 6.8% on average across the report.

What is 10x Genomics’s 52-week high and low?

10x Genomics’s 52-week high is $102.81 and its 52-week low is $15.12; it closed at $58.19 on Nov 13, 2026, +248.7% over the past year. Over the last five years the shares peaked at $167.49 on Nov 15, 2021.

Is 10x Genomics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in 10x Genomics?

Gekko flagged 1 unusual options signal in 10x Genomics over the last 30 days, with $2.18M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 29, 2026 with $2.18M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See 10x Genomics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.